Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
|Articles|April 7, 2023
Pharma USA 2023: What Medicare Reform Means to Patient Access Network Foundation
Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes that impact Medicare, as well as the Foundation's near-term goals.
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on how the Foundation will address its near- and longer-term goals.
Advertisement
Related to this article
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
Pharmaceutical Executive Daily: FDA Approves Fayuvi
3
The Battle to Own the GLP-1 Patient Journey
4
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
5